



January 30, 2024

British Columbia Securities Commission
Alberta Securities Commission
Ontario Securities Commission

Dear Sirs/Mesdames:

Re: BriaCell Therapeutics Corp. (the "Company" or "BriaCell")
Report of Voting Results pursuant to section 11.3 of National Instrument 51-102 –
Continuous Disclosure Obligations ("NI 51-102")

This report describes the matters voted upon and the outcome of the votes at the annual general meeting of shareholders of the Company held on January 30, 2024. Shareholders of the Company were entitled to attend and participate in the meeting in person. The matters set out below are described in greater detail in the proxy statement of the Company dated December 27, 2023 (the "**Proxy Statement**"), which is available on SEDAR+ (<https://www.sedarplus.ca>) under BriaCell's issuer profile.

A total of 5,375,071 common shares of the Company ("**Common Shares**") representing 33.63% of the Company's issued and outstanding Common Shares were voted in connection with the Meeting.

	<u>Outcome of Vote</u>	<u>Votes For</u>	<u>Votes Withheld</u>
1. Appointment of MNP LLP, as auditors of the Company and authorizing the directors to fix their remuneration.	Approved	5,346,102 (99.46%)	28,968 (0.54%)
	<u>Outcome of Vote</u>	<u>Votes For</u>	<u>Votes Withheld</u>
2. The election of the following directors:			
(a) Dr. William V. Williams	Approved	3,487,704 (99.71%)	10,251 (0.29%)
(b) Mr. Jamieson Bondarenko	Approved	3,302,543 (94.41%)	195,412 (5.59%)
(c) Dr. Rebecca Taub	Approved	3,491,351 (99.81%)	6,604 (0.19%)
(d) Mr. Vaughn C. Embro-Pantalony	Approved	3,489,398 (99.76%)	8,557 (0.24%)

(e)	Mr. Martin Schmieg	Approved	3,486,913 (99.68%)	11,042 (0.32%)
(f)	Mr. Marc Lustig	Approved	3,221,128 (92.09%)	276,827 (7.91%)
(g)	Dr. Jane Gross	Approved	3,491,308 (99.81%)	6,647 (0.19%)

BRIACELL THERAPEUTICS CORP.

(signed) "Jamieson Bondarenko"

Jamieson Bondarenko
Chairman of the Board of Directors